Major Integrase Inhibitor (INI) Resistance Mutations
The table lists the most common clinically significant INI-resistance mutations. Mutations in bold red are associated with the highest levels of reduced susceptibility or virological response to the indicated INI. Mutations in bold reduce INI susceptibility or virological response. Mutations in plain text contribute to reduced suceptibility in combination with other INI-resistance mutations.
T66I is a nonpolymorphic mutation selected in vitro (1,2,3,4,5) and in patients receiving EVG (1,2,3,6,7) T66I reduces EVG susceptibility by ~10-fold (8,4,9,10,11) but does not reduce RAL (8,9,4,10,12) or DTG susceptibility (11,13).
T66K is a nonpolymorphic mutation selected in vitro (4) and in vivo (14) by EVG. It is associated with 40-80-fold reduced EVG susceptibility (8,4,11), 10-20-fold reduced RAL susceptibility (8,4,11) and 2-to-3-fold reduced DTG susceptibility (8,11).
T66A is a nonpolymorphic mutation selected in vivo by EVG (15,14,7) and RAL (16,17,15) usually in combination with other INSTI-resistance mutations. It reduces EVG susceptibility ~5-fold but has minimal if any effect on RAL or DTG susceptibility (8,4,10,11,12).
E92Q is a nonpolymorphic mutation selected in patients receiving RAL (18,15,6,7) and EVG (15,14,19,6). It reduces RAL susceptibility >5-fold (8,9,10,11) and EVG susceptibility >30-fold depending on the assay and genetic context (2,8,9,10,11,20). It is often the primary mutation associated with virological failure on an EVG-containing regimen (6,7). It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold (8,11,20).
E92G is a rare nonpolymorphic mutation selected in vitro (4) and in vivo by EVG (7,11). It reduces EVG susceptibility ~10-fold (4,11) but does not reduce RAL or DTG susceptibility (4,11). E92V has been selected in vitro by an investigational INSTI and reported to reduce RAL and EVG susceptibility by 10 and 40-fold, respectively (9). It has not been reported in patients receiving RAL, EVG, or DTG.
E138K/A are nonpolymorphic accessory resistance mutations selected in patients receiving RAL (18,21,22), EVG (14), and DTG (23). They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility (1,9), however, they are associated with >100-fold reduced RAL and EVG susceptibility and up to 10-fold reduced DTG susceptibility when they occur with Q148 mutations (24,25,23,26,20). E138T is a less common nonpolymorphic INSTI-selected mutation that appears to have effects similar to E138K/A (22,27).
E138D is a polymorphism that occurs in 1% to 2% of viruses from INSTI-naive patients and does not appear to be selected by INSTIs or to reduce INSTI susceptibility (22).
G140S is a nonpolymorphic mutation that usually occurs in combination with Q148H/R/K in patients receiving RAL (18,28,15,29,30,16) and EVG (14,6). Alone it does not reduce INSTI susceptibility. However, in combination with Q148 mutations, it is associated with a >100-fold reduced RAL and EVG susceptibility and up to 10-fold reduced DTG susceptibility. (24,25,26,20). G140A/C are less well-studied INSTI-selected nonpolymorphic mutations that appear to have effects similar to G140S (31,32,20).
Y143C/R are nonpolymorphic mutations selected by RAL (28,18,33,30,34,28,35,29). Alone, Y143C and Y143R reduce RAL susceptibility by ~5 and 20-fold respectively (18,34,25,28,29) but in combination with T97A or other accessory mutations, they reduce RAL susceptibility >100-fold (24,28,18,34). Y143H is a less common mutation at this position. It is likely a transitional mutation between the wildtype Y and the 2-base pair mutant R.
Alone, Y143C/R mutations have minimal effects on EVG susceptibility (8,11,29,10). However, in combination with accessory INSTI-resistance mutations particularly T97A, they are associated with a 10 to 20-fold reduction in EVG susceptibility (36). Y143 mutations do not reduce DTG susceptibility (29,12,10).
Q148H/K/R are nonpolymorphic mutations selected in patients receiving RAL and EVG (37,28,7,15,24,30,29,38,39,16). Alone Q148H reduces RAL and EVG susceptibility about 5-10 fold and Q148R/K reduce RAL and EVG susceptibility 30-100 fold (24,8,11,3,40,29,25). In combination with G140S/A, Q148H/R/K reduce RAL and EVG susceptibility >100-fold. (24,8,11,3,40,29,25). Alone Q148H/K/R have minimal effects on DTG susceptibility (8,26,11). However, in combination with E138K/A/T or G140S/A, they cause >10-fold reduced DTG susceptibility (8,23,26,11). Q148N is a rare INSTI-selected mutation that causes low-level EVG resistance. It may represent a Q148H or Q148K revertant (41).
In subtype B viruses G140 is encoded primarily by GGT or GGC whereas for nearly all other subtypes, G140 is encoded primarily by GGG or GGA. Therefore, a single G to A change at the first position of the G140 codon results in a serine in subtype B viruses. G140S is an important compensatory mutation for Q148 mutations and this may explain why Q148 mutations occur significantly more commonly in subtype B viruses compared to non-B viruses in patients with RAL VF (42,43,44).
N155H is a nonpolymorphic mutation selected in patients receiving RAL and EVG (37,28,7,15,24,30,29,38,39,16,14,6,7,32). Alone, it reduces RAL susceptibility >10-fold and EVG susceptibility >30-fold (8,4,9,28,10,24,20).
N155H is selected by DTG in RAL-experienced patients (23). There have also been several reports of VF on DTG in patients who had N155H at baseline and developed additional INSTI-resistance mutations (45,46).
N155ST are extremely rare nonpolymorphic INSTI-resistance mutations that reduce RAL and EVG susceptibility somewhat less than that of N155H (8,9,12,8). N155D is a nonpolymorphic RAL-selected mutation that has not been studied.
H51Y is a rare nonpolymorphic accessory mutation selected in vitro by EVG (2,1,4) and DTG (47) and in patients receiving RAL (15,48) and EVG (6). It reduces EVG susceptibility by 2-3-fold (2,4,47,34) but alone does not appear to reduce RAL or DTG susceptibility (4,47). In combination with R263K, it has been reported to reduce DTG susceptibility 7-fold (47).
L74M/I are highly polymorphic accessory INSTI-resistance mutation selected in patients receiving RAL (18,37,29,39) and EVG (15). In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients, depending on subtype. L74M/I are also selected by DTG in patients previously treated with RAL who have primary DTG-associated mutations (23,49,27). Alone, these mutations have minimal if any effect on INSTI susceptibility (9,40). However, in combination with other primary resistance mutations they appear to contribute to reduced susceptibility to each of the INSITs (5,9,48,49,27).
T97A is a polymorphic accessory INSTI-resistance mutation that occurs in 1% to 4% of viruses from untreated persons depending on subtype (50). It is selected by RAL (51,30,7) and EVG (7). In site-directed mutagenesis studies, it has minimal if any effect on INSTI susceptibility. However, in a recent analysis of clinical isolates from the U.S., it was associated with 5 to 10-fold reduced susceptibility to RAL and EVG, possibly because many of these isolates may have been from INSTI-treated patients whose viruses had other accessory resistance mutations or minority variant primary resistance mutations (20). T97A synergistically reduces RAL and EVG susceptibility in combination with Y143CR (36,24,20). T97A is selected by DTG in RAL-experienced patients with primary DTG-associated mutations (23,49,27).
V151I occurs in 5% of subtype B viruses from ARV-naive patients but is nonpolymorphic in most other subtypes. It is selected in patients receiving RAL (18) and in vitro by EVG (5). It appears to have little or no effect on INSTI susceptibility (53). V151L is an extremely rare nonpolymorphic mutation selected in vitro by early investigational INSTIs but not in patients receiving currently approved INSTIs. It reduces susceptibility to RAL, EVG, and DTG by ~10, ~40, and 3.6-fold, respectively (8). V151A is also an extremely rare nonpolymorphic mutation selected in vitro by an investigational INSTI. It reduces susceptibility to RAL by 4-fold and to EVG by 12-fold (9).
E157Q is a polymorphic mutation selected in patients receiving RAL (51) and in vitro by EVG (2). It has also been reported in a patient with virological failure on a DTG-containing regimen (55). It appears to reduce RAL and EVG susceptibility by 2- to 3-fold (40,34) and to increase DTG susceptibility (56).
G163R/K are nonpolymorphic in all subtypes except subtype F (50,22). G163R/K are selected in subtype B viruses from RAL-experienced patients. They are accessory mutations that usually occur in combination with other INSTI-resistance mutations particularly N155H (18,17,37).
Its reported effects on in vitro susceptibility have been highly variable. In combination with L74M the virus was found to be associated with ~10-fold reduced RAL susceptibility and lower levels of reduced EVG susceptibility (5,57,34). In site directed mutants, it has been found in one study to have no effect on INSTI susceptibility (58). However, in other studies, it has been reported to cause 5 to 20-fold reduced susceptibility to each of the INSTIs (60,59,61,62).
G118R is also commonly observed in sequences with G-to-A hypermutation and in this setting it should be considered a result of lethal APOBEC-mediated virus editing and not an indicator of drug resistance (22).
F121Y is a nonpolymorphic mutation that is selected in vitro by RAL (63) and EVG (2) and rarely in vivo by RAL (64) It reduces susceptibility to RAL and EVG by about 10 and 30-fold, respectively (2,5,20). Most studies suggest that it does not reduce DTG susceptibility (65,61,62,20).
R263K is a rare nonpolymorphic mutation selected in vitro by EVG (4) and DTG (47,67). R263K is extremely rare in patients receiving RAL occurring in 6 of 893 patients in HIVDB and in 0/502 in another study (42). However, R263K did develop in two clinical trial patients receiving DTG plus an optimized background regimen (68). R263K rarely occurs with other DRMs and also appears to have reduced replication (69). It reduces DTG and EVG susceptibility ~2-fold and 6-fold, respectively but has minimal if any effect on RAL susceptibility (47,67,29,4).
V54I is a minimally polymorphic mutation (50) selected in vitro (40) and rarely in vivo by RAL (22). L68V is a polymorphic accessory mutation selected in vivo by EVG (15,1,6). In combination with E92Q, it contributes reduced EVG susceptibility (1). H114Y is an extremely rare nonpolymorphic mutation (50) selected in vitro by EVG (3). A128T is a nonpolymorphic mutation selected in vitro by EVG, but which does not appear to reduce INSTI susceptibility (3,53).
- 1.0 1.1 1.2 1.3 1.4 1.5 McColl DJ and Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res 2010.
- 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 2.11 2.12 Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S and Matsuoka M. Broad anti-retroviral activity and resistance profile of a novel human immunodeficiency virus integrase inhibitor, elvitegravir (JTK-303/GS-9137). J Virol 2007.
- 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, Dockx K, Strijbos R, Smits V, Vos A, Meersseman G, Jochmans D, Vermeire K, Schols D, Hallenberger S and Hertogs K. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008.
- 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 Margot NA, Hluhanich RM, Jones GS, Andreatta KN, Tsiang M, McColl DJ, White KL and Miller MD. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res 2012.
- 5.0 5.1 5.2 5.3 5.4 5.5 Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, Wakasa-Morimoto C, Kodama M, Endoh T, Oosugi E, Matsushita Y, Murai H, Fujishita T, Yoshinaga T, Garvey E, Foster S, Underwood M, Johns B, Sato A and Fujiwara T. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res 2008.
- 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 White K, Abram ME Kulkarni R, Rhee M, Szwarcberg J and Miller, MD. Emergent drug resistance from the HIV-1 phase 3 elvitegravir/cobicistat/emtricitabine.tenofovir disoproxil fumarate studies through week 96 [Abstract 596]. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA 2013.
- 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9 7.10 Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK and Chuck SL. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012.
- 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.11 8.12 8.13 8.14 8.15 8.16 8.17 8.18 8.19 8.20 8.21 Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A and Fujiwara T. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011.
- 9.0 9.1 9.2 9.3 9.4 9.5 9.6 9.7 9.8 9.9 9.10 Jones GS, Yu F, Zeynalzadegan A, Hesselgesser J, Chen X, Chen J, Jin H, Kim CU, Wright M, Geleziunas R and Tsiang M. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 2009.
- 10.0 10.1 10.2 10.3 10.4 10.5 10.6 10.7 10.8 Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, Smits V, Cleybergh C, De Wolf H, Van Baelen K and Stuyver LJ. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob Agents Chemother 2011.
- 11.0 11.1 11.2 11.3 11.4 11.5 11.6 11.7 11.8 11.9 11.10 11.11 11.12 11.13 11.14 11.15 11.16 11.17 Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL and Miller MD. Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness. Antimicrob Agents Chemother 2013.
- 12.0 12.1 12.2 12.3 Van der Borght K, Verheyen A, Feyaerts M, Van Wesenbeeck L, Verlinden Y, Van Craenenbroeck E and van Vlijmen H. Quantitative prediction of integrase inhibitor resistance from genotype through consensus linear regression modeling. Virol J 2013.
- ^ Liang J, Mesplede T, Oliveira M, Anstett K and Wainberg MA. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance. J Virol 2015.
- 14.0 14.1 14.2 14.3 14.4 14.5 14.6 14.7 Winters MA, Lloyd RM, Jr, Shafer RW, Kozal MJ, Miller MD and Holodniy M. Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. PLoS One 2012.
- 15.0 15.1 15.2 15.3 15.4 15.5 15.6 15.7 15.8 15.9 Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R, Martin JN, Lalezari J, Bangsberg D, Petropoulos C and Deeks SG. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr 2010.
- 16.0 16.1 16.2 16.3 Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Belec L, Weiss L, Si-Mohamed A and Piketty C. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008.
- 17.0 17.1 Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, Gonzalez CJ, Danovich RM, Wan H, Zhao J, Meibohm AR, Strohmaier KM, Harvey CM, Isaacs RD and Nguyen BY. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr 2010.
- 18.0 18.1 18.2 18.3 18.4 18.5 18.6 18.7 18.8 18.9 18.10 Blanco JL, Varghese V, Rhee SY, Gatell JM and Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011.
- ^ DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK and Kearney BP. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012.
- 20.0 20.1 20.2 20.3 20.4 20.5 20.6 20.7 20.8 20.9 White K, Cihlar T and Miller MD. Activity of Bictegravir (BIC; GS-9883), a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance. 14th European Workshop on HIV & Hepatitis, May 25-27, 2016, Rome, Italy 2016.
- ^ da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H and Masquelier B. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 2010.
- 22.0 22.1 22.2 22.3 22.4 22.5 Rhee SY, Sankaran K, Varghese V, Winters M, Hurt CB, Eron JJ, Parkin N, Holmes SP, Holodniy M and Shafer RW. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation. J Virol 2016.
- 23.0 23.1 23.2 23.3 23.4 23.5 Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C and Yeo J. Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study. J Infect Dis 2013.
- 24.0 24.1 24.2 24.3 24.4 24.5 24.6 24.7 24.8 Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, Petropoulos CJ and Huang W. Loss of raltegravir susceptibility of HIV-1 is conferred by multiple non-overlapping genetic pathways. J Virol 2009.
- 25.0 25.1 25.2 25.3 25.4 25.5 25.6 Canducci F, Ceresola ER, Boeri E, Spagnuolo V, Cossarini F, Castagna A, Lazzarin A and Clementi M. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis 2011.
- 26.0 26.1 26.2 26.3 Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG and Fujiwara T. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr 2012.
- 27.0 27.1 27.2 27.3 Naeger LK, Harrington P, Komatsu T and Deming D. Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients. Antivir Ther 2016.
- 28.0 28.1 28.2 28.3 28.4 28.5 28.6 28.7 Fransen S, Gupta S, Frantzell A, Petropoulos CJ and Huang W. Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo. J Virol 2012.
- 29.0 29.1 29.2 29.3 29.4 29.5 29.6 29.7 29.8 29.9 29.10 Garrido C, Villacian J, Zahonero N, Pattery T, Garcia F, Gutierrez F, Caballero E, Van Houtte M, Soriano V and de Mendoza C. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 2012.
- 30.0 30.1 30.2 30.3 30.4 Canducci F, Marinozzi MC, Sampaolo M, Boeri E, Spagnuolo V, Gianotti N, Castagna A, Paolucci S, Baldanti F, Lazzarin A and Clementi M. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J Antimicrob Chemother 2010.
- ^ Garrido C, Soriano V, Geretti AM, Zahonero N, Garcia S, Booth C, Gutierrez F, Viciana I and de Mendoza C. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience. Antiviral Res 2011.
- 32.0 32.1 Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, Baril JG, Wainberg MA and Roger M. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol 2011.
- ^ Metifiot M, Marchand C, Maddali K and Pommier Y. Resistance to integrase inhibitors. Viruses 2010.
- 34.0 34.1 34.2 34.3 34.4 34.5 34.6 Geretti AM, Armenia D and Ceccherini-Silberstein F. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis 2012.
- ^ Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, Sayon S, Calvez V, Deprez E, Marcelin AG, Tchertanov L and Mouscadet JF. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother 2010.
- 36.0 36.1 36.2 Huang W, Frantzell A, Fransen S and Petropoulos CJ. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir. Antimicrob Agents Chemother 2013.
- 37.0 37.1 37.2 37.3 Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H and Nguyen BY. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008.
- 38.0 38.1 Parczewski M, Bander D, Urbanska A and Boron-Kaczmarska A. HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland. BMC Infect Dis 2012.
- 39.0 39.1 39.2 Wittkop L, Breilh D, Da Silva D, Duffau P, Mercie P, Raymond I, Anies G, Fleury H, Saux MC, Dabis F, Fagard C, Thiebaut R, Masquelier B and Pellegrin I. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. J Antimicrob Chemother 2009.
- 40.0 40.1 40.2 40.3 40.4 Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, Hertogs K and Clayton R. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology 2010.
- ^ Varghese V, Pinsky BA, Smith DS, Klein D and Shafer RW. Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility. AIDS Res Hum Retroviruses 2016.
- 42.0 42.1 Fourati S, Charpentier C, Amiel C, Morand-Joubert L, Reigadas S, Trabaud MA, Delaugerre C, Nicot F, Rodallec A, Maillard A, Mirand A, Jeulin H, Montes B, Barin F, Bettinger D, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Descamps D, Calvez V, Flandre P, Marcelin AG and Group, Anrs Ac Resistance Study. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. J Antimicrob Chemother 2015.
- ^ Doyle T, Dunn DT, Ceccherini-Silberstein F, De Mendoza C, Garcia F, Smit E, Fearnhill E, Marcelin AG, Martinez-Picado J, Kaiser R, Geretti AM and Group, Coronet Study. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. J Antimicrob Chemother 2015.
- ^ Boyd MA, Moore CL, Molina JM, Wood R, Madero JS, Wolff M, Ruxrungtham K, Losso M, Renjifo B, Teppler H, Kelleher AD, Amin J, Emery S, Cooper DA and group, Second-Line study. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Lancet HIV 2015.
- ^ Carganico A, Dupke S, Ehret R, Berg T, Baumgarten A, Obermeier M and Walter H. New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy. J Int AIDS Soc 2014.
- ^ Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, Moisi D, Wainberg MA and Roger M. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother 2015.
- 47.0 47.1 47.2 47.3 47.4 47.5 Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W and Wainberg MA. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 2013.
- 48.0 48.1 Reuman EC, Bachmann MH, Varghese V, Fessel WJ and Shafer RW. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob Agents Chemother 2010.
- 49.0 49.1 49.2 and FDA. Tivicay (dolutegravir) prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf 2015.
- 50.0 50.1 50.2 50.3 Varghese V, Liu TF, Rhee SY, Libiran P, Trevino C, Fessel WJ and Shafer RW. HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses 2010.
- 51.0 51.1 Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V and Marcelin AG. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008.
- 52.0 52.1 Fun A, Van Baelen K, van Lelyveld SF, Schipper PJ, Stuyver LJ, Wensing AM and Nijhuis M. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity. J Antimicrob Chemother 2010.
- 53.0 53.1 Low A, Prada N, Topper M, Vaida F, Castor D, Mohri H, Hazuda D, Muesing M and Markowitz M. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother 2009.
- ^ Vavro C, Hasan S, Madsen H, Horton J, DeAnda F, Martin-Carpenter L, Sato A, Cuffe R, Chen S, Underwood M and Nichols G. Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572). Antimicrob Agents Chemother 2013.
- ^ Danion F, Belissa E, Peytavin G, Thierry E, Lanternier F, Scemla A, Lortholary O, Delelis O, Avettand-Fenoel V and Duvivier C. Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region. J Antimicrob Chemother 2015.
- ^ Anstett K, Cutillas V, Fusco R, Mesplede T and Wainberg MA. Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. J Antimicrob Chemother 2016.
- 57.0 57.1 Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vezinet F, Perno CF, Descamps D, Capt A, Calvez V and Marcelin AG. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother 2011.
- 58.0 58.1 58.2 Brenner BG, Thomas R, Blanco JL, Ibanescu RI, Oliveira M, Mesplede T, Golubkov O, Roger M, Garcia F, Martinez E and Wainberg MA. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. J Antimicrob Chemother 2016.
- 59.0 59.1 Quashie PK, Oliviera M, Veres T, Osman N, Han YS, Hassounah S, Lie Y, Huang W, Mesplede T and Wainberg MA. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J Virol 2015.
- ^ Quashie PK, Mesplede T, Han YS, Veres T, Osman N, Hassounah S, Sloan RD, Xu HT and Wainberg MA. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother 2013.
- 61.0 61.1 Malet I, Gimferrer Arriaga L, Artese A, Costa G, Parrotta L, Alcaro S, Delelis O, Tmeizeh A, Katlama C, Valantin MA, Ceccherini-Silberstein F, Calvez V and Marcelin AG. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother 2014.
- 62.0 62.1 Munir S, Thierry E, Malet I, Subra F, Calvez V, Marcelin AG, Deprez E and Delelis O. G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance. J Antimicrob Chemother 2015.
- ^ and Rowley M. The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection. Prog Med Chem 2008.
- ^ Souza Cavalcanti J, Minhoto Lanca A, de Paula Ferreira JL, da Eira M, de Souza Dantas DS and de Macedo Brigido LF. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen. Antiviral Res 2012.
- ^ Yoshinaga T, Kobayashi M, Seki T, Miki S, Wakasa-Morimoto C, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A and Fujiwara T. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother 2015.
- ^ Garvey EP, Johns BA, Gartland MJ, Foster SA, Miller WH, Ferris RG, Hazen RJ, Underwood MR, Boros EE, Thompson JB, Weatherhead JG, Koble CS, Allen SH, Schaller LT, Sherrill RG, Yoshinaga T, Kobayashi M, Wakasa-Morimoto C, Miki S, Nakahara K, Noshi T, Sato A and Fujiwara T. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother 2008.
- 67.0 67.1 Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR and Wainberg MA. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012.
- ^ Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C and Min S. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013.
- ^ Anstett K, Mesplede T, Oliveira M, Cutillas V and Wainberg MA. Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions. J Virol 2015.